AGL 5.75 Decreased By ▼ -0.08 (-1.37%)
ANL 9.08 Increased By ▲ 0.05 (0.55%)
AVN 79.25 Increased By ▲ 0.45 (0.57%)
BOP 5.21 Increased By ▲ 0.05 (0.97%)
CNERGY 4.73 Increased By ▲ 0.05 (1.07%)
EFERT 81.22 Increased By ▲ 0.67 (0.83%)
EPCL 50.87 Decreased By ▼ -0.84 (-1.62%)
FCCL 13.51 Decreased By ▼ -0.10 (-0.73%)
FFL 5.82 Decreased By ▼ -0.03 (-0.51%)
FLYNG 7.25 Increased By ▲ 0.13 (1.83%)
FNEL 4.80 Decreased By ▼ -0.05 (-1.03%)
GGGL 8.90 No Change ▼ 0.00 (0%)
GGL 15.82 Decreased By ▼ -0.23 (-1.43%)
HUMNL 5.88 Increased By ▲ 0.08 (1.38%)
KEL 2.59 Decreased By ▼ -0.01 (-0.38%)
LOTCHEM 29.98 Decreased By ▼ -0.03 (-0.1%)
MLCF 25.28 Decreased By ▼ -0.12 (-0.47%)
OGDC 72.63 Increased By ▲ 0.48 (0.67%)
PAEL 15.43 Decreased By ▼ -0.06 (-0.39%)
PIBTL 5.13 Increased By ▲ 0.12 (2.4%)
PRL 16.48 Increased By ▲ 0.08 (0.49%)
SILK 1.09 Decreased By ▼ -0.01 (-0.91%)
TELE 9.53 Decreased By ▼ -0.12 (-1.24%)
TPL 7.40 Increased By ▲ 0.10 (1.37%)
TPLP 19.29 Increased By ▲ 0.06 (0.31%)
TREET 21.87 Decreased By ▼ -0.08 (-0.36%)
TRG 144.68 Decreased By ▼ -0.29 (-0.2%)
UNITY 17.56 Increased By ▲ 0.94 (5.66%)
WAVES 10.01 Increased By ▲ 0.01 (0.1%)
WTL 1.37 No Change ▼ 0.00 (0%)
BR100 4,258 Increased By 27.9 (0.66%)
BR30 15,841 Increased By 19.2 (0.12%)
KSE100 42,374 Increased By 302.3 (0.72%)
KSE30 15,665 Increased By 161 (1.04%)
Business & Finance

Moderna says its COVID-19 vaccine found safe, effective in teens

  • Moderna Inc, whose vaccine is authorized for adults 18 and older, said it will submit the findings of its adolescent study to the US Food and Drug Administration and other regulators for emergency use authorization in early June.
  • US regulators took about a month to review a similar study from Pfizer/BioNtech, which was authorized for ages 12-15 on May 10. If Moderna gets the same treatment, its authorization would come in early July.
Published May 25, 2021
Follow us

CHICAGO: Moderna's COVID-19 vaccine was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial, the developer said on Tuesday, potentially setting the stage for a second vaccine for school-aged children to be authorized in July.

Moderna Inc, whose vaccine is authorized for adults 18 and older, said it will submit the findings of its adolescent study to the US Food and Drug Administration and other regulators for emergency use authorization in early June.

US regulators took about a month to review a similar study from Pfizer/BioNtech, which was authorized for ages 12-15 on May 10. If Moderna gets the same treatment, its authorization would come in early July.

Most children with COVID-19 develop only mild symptoms or no symptoms. Yet children remain at risk of becoming seriously ill, and they can spread the virus. Widely vaccinating 12- to 18-year olds could allow US schools and summer camps to relax masking and social distancing measures suggested by the CDC.

"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents," Stéphane Bancel, Moderna's chief executive, said in a statement.

Moderna's trial evaluated the vaccine in 3,732 adolescents aged 12 to 17, two thirds of whom got the vaccine and one third of whom got a placebo. The main goal was to produce an immune response on par with that seen in the company's large, Phase 3 trial in adults, which was 94.1% effective at preventing COVID-19.

Two weeks after the second dose, researchers found no cases of COVID-19 in the vaccine group compared to 4 cases in the placebo group, resulting in a vaccine efficacy of 100%, based on case definitions from the company's adult trial.

Using a case definition from the US Centers for Disease Control and Prevention, which requires only 1 COVID-19 symptom, the vaccine was found to be 93% effective, suggesting the vaccine may be protective against cases with milder symptoms, the company said.

The researchers found no new safety issues. The most common side effects after the second dose were headache, fatigue, body aches and chills.

The company said it is still accumulating safety data. All study participants will be monitored for 12 months after their second dose to determine long-term protection and safety.

Moderna said it plans to submit the data to a peer-reviewed publication. The company is currently testing its vaccine in children as young as 6 months of age.

In addition to the United States, Pfizer's vaccine is also authorized for use in younger teens aged 12 to 15 in Canada and Algeria.

Comments

Comments are closed.

Moderna says its COVID-19 vaccine found safe, effective in teens

Gen Qamar Javed Bajwa hands over baton of command to Gen Asim Munir

Rupee remains stable at 223.95 against US dollar

Hina Rabbani Khar meets interim Afghan government leadership on one-day Kabul trip

Oil jumps on hopes for easing in China’s COVID controls

Islamabad court extends Azam Swati’s remand for 4 days

EPCL enters into interim agreement with SSGC for gas supply

Qatar agrees long-term gas supply deal with Germany: energy minister

S&P Global lowers 2023 growth forecast for emerging markets

PD prepares $496m gas pipeline augmentation plan

IMF, govt begin virtual engagement